Asgard Therapeutics is a spin-off from Lund University, Sweden, aiming to advance cancer immunotherapies by harnessing direct cell fate reprogramming technologies. Our lead program, TrojanDC, is a paradigm-shifting gene therapy that reprograms cancer cells into antigen-presenting dendritic cells, unleashing the immune system against cancer. Asgard is building a multidisciplinary team that understands the value and opportunities of working in a startup based in a unique platform technology. We are looking for team members who are creative and passionate about making a contribution to the cancer immunotherapy field and improve patients’ lives.
We are seeking a highly enthusiastic and innovative Scientist/Senior Scientist searching for an opportunity to help building an early-stage company and contribute to the development of next generation cancer immunotherapies. The successful candidate should have the ability to design experiments autonomously, analyze complex data, troubleshoot technical issues, and supervise junior staff. Strong interpersonal, verbal and written communication skills are required. Experimental rigor, scientific curiosity and ability to work in a fast-paced environment, adapting to evolving priorities are musts. The position will be lab-based and research activities will be performed in collaboration with the Cell Reprogramming in Hematopoiesis and Immunity Lab at Lund University (http://www.pereiralab.com/).
Scientist/Senior Scientist with background in gene therapy vector development and validation to help establishing a best-in-class in vivo reprogramming delivery platform. The candidate will develop and test viral and non-viral delivery systems to deliver reprogramming factors. The ideal candidate should have a proven track record in developing gene therapies, preferentially applied in vivo or in situ, as well as a broad understanding of viral-based immunotherapies and their applications to cancer treatment.
Rosa FF, Pires CF, Kurochkin I, Ferreira AG, Gomes A, Palma LG, Shaiv K, Solanas L, Azenha C, Papatsenko D, Schulz O, Reis e Sousa C, Pereira CF. Direct Reprogramming Fibroblasts into Antigen-Presenting Dendritic Cells. Science Immunology 2018, 7, 3 (30).
Pires CF, Rosa FF, Kurochkin I and Pereira C-F (2019) Understanding and Modulating Immunity With Cell Reprogramming. Front. Immunol. 10:2809. doi: 10.3389/fimmu.2019.02809.
Application: Please email your CV, cover letter and contact information for two references to email@example.com to apply. Asgard will review applications on a rolling basis and only shortlisted candidates will be contacted.
|Job type||Full time|
|Salary||Commensurate with role and experience.|